CATX
Perspective Therapeutics, Inc. · Healthcare · Medical - Devices
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -3.9% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 200 | $544 | n/a | n/a |
| Q2 2026 | 58 | -4 | 46.70M | $159.34M | +6 | −11 |
| Q1 2026 | 65 | +7 | 36.59M | $152.45M | +14 | −7 |
| Q4 2025 | 58 | +1 | 24.82M | $68.26M | +2 | −1 |
| Q3 2025 | 14 | 0 | 27.71M | $95.03M | +1 | −1 |
| Q2 2025 | 11 | 0 | 24.99M | $85.98M | +1 | −1 |
| Q1 2025 | 8 | -1 | 4.80M | $10.23M | +1 | −2 |
| Q4 2024 | 9 | +2 | 5.35M | $17.08M | +3 | −1 |
| Q3 2024 | 6 | -2 | 3.54M | $47.23M | +1 | −3 |
| Q2 2024 | 8 | n/a | 3.80M | $37.75M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 10.01M | -9.8% | $34.34M | 0.0% | ▼ Trim | 2 | SEC ↗ ×4 |
| 2 | BlackRock ✦ (passive) | 4.37M | +1.7% | $14.98M | 0.0% | ▲ Add | 2 | SEC ↗ ×7 |
| 3 | The Vanguard Group ✦ (passive) | 3.44M | +5.0% | $11.79M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 4 | Morgan Stanley ✦ | 2.76M | n/a | $9.47M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 5 | Millennium Management ✦ | 2.56M | -1.2% | $8.78M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 1.43M | +3.6% | $4.91M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | State Street Global Advisors ✦ (passive) | 1.10M | +1.5% | $3.79M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | JPMorgan Chase ✦ | 872.71K | n/a | $2.99M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 9 | Two Sigma Investments ✦ | 519.67K | -13.7% | $1.78M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 10 | Wellington Management ✦ | 206.63K | New | $708,748 | 0.0% | New | 1 | SEC ↗ ×3 |
| 11 | Goldman Sachs Group ✦ | 197.71K | n/a | $678,145 | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 12 | Citadel Advisors ✦ | 160.66K | +261.4% | $551,067 | 0.0% | ▲ Add | 6 | SEC ↗ |
| 13 | Point72 Asset Management ✦ | 44.23K | -26.3% | $151,721 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 29.77K | +3.4% | $103,000 | 0.0% | ▲ Add | 6 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Wellington Management | $708,748 | 0.0% |
Exited
| Marshall Wace | $1.79M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 135 holders, 78.53M shares, $325.34M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
10% owner · 167.15K sh · $526,051
10% owner · 80.78K sh · $250,896
10% owner · 42.13K sh · $131,219
10% owner · 35.77K sh · $111,574
10% owner · 78.14K sh · $245,610
10% owner · 78.14K sh · $245,610
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
7.7% of class · View original SEC filing ↗
10.0% of class · View original SEC filing ↗